Armistice Capital LLC Sells 72,000 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Armistice Capital LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,764,000 shares of the specialty pharmaceutical company’s stock after selling 72,000 shares during the period. Supernus Pharmaceuticals makes up about 1.6% of Armistice Capital LLC’s portfolio, making the stock its 7th biggest position. Armistice Capital LLC’s holdings in Supernus Pharmaceuticals were worth $137,371,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after acquiring an additional 4,729 shares during the period. AQR Capital Management LLC grew its stake in Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after purchasing an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after purchasing an additional 1,297 shares during the period. Millennium Management LLC raised its stake in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC raised its stake in shares of Supernus Pharmaceuticals by 16.0% in the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $43.58 on Thursday. Supernus Pharmaceuticals, Inc. has a 52-week low of $30.83 and a 52-week high of $59.68. The stock has a market cap of $2.53 billion, a PE ratio of -85.45, a price-to-earnings-growth ratio of 0.93 and a beta of 0.55. The business has a 50-day simple moving average of $48.27 and a 200-day simple moving average of $49.51.

Analyst Ratings Changes

A number of equities research analysts recently commented on SUPN shares. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.